Please login to the form below

Not currently logged in
Email:
Password:

cilengitide

This page shows the latest cilengitide news and features for those working in and with pharma, biotech and healthcare.

Glioblastomas - a personalised future?

Glioblastomas - a personalised future?

Another angiogenesis inhibitor, cilengitide, is in phase 3 development in Germany and the US in combination with temozolomide and radiation therapy, in newly diagnosed patients, and phase 2 in Germany in

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics